Halozyme Therapeutics reported quarterly EPS of $1.60, topping the Zacks Consensus Estimate of $1.54 by $0.06 per share. Earnings also improved from $1.11 per share a year ago, indicating year-over-year profitability growth. The print is a modest positive for the stock and may support a small near-term move.
Halozyme Therapeutics reported quarterly EPS of $1.60, topping the Zacks Consensus Estimate of $1.54 by $0.06 per share. Earnings also improved from $1.11 per share a year ago, indicating year-over-year profitability growth. The print is a modest positive for the stock and may support a small near-term move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.36
Ticker Sentiment
